Publications

Detailed Information

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

DC Field Value Language
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorVan Cutsem, Eric-
dc.contributor.authorFuchs, Charles S.-
dc.contributor.authorOhtsu, Atsushi-
dc.contributor.authorTabernero, Josep-
dc.contributor.authorIlson, David H.-
dc.contributor.authorHyung, Woo Jin-
dc.contributor.authorStrong, Vivian E.-
dc.contributor.authorGoetze, Thorsten Oliver-
dc.contributor.authorYoshikawa, Takaki-
dc.contributor.authorTang, Laura H.-
dc.contributor.authorHwang, Peggy May Tan-
dc.contributor.authorWebb, Nancy-
dc.contributor.authorAdelberg, David-
dc.contributor.authorShitara, Kohei-
dc.date.accessioned2021-01-31T11:10:08Z-
dc.date.available2021-01-31T11:10:08Z-
dc.date.created2019-09-27-
dc.date.issued2019-03-
dc.identifier.citationFuture Oncology, Vol.15 No.9, pp.943-952-
dc.identifier.issn1479-6694-
dc.identifier.other84747-
dc.identifier.urihttps://hdl.handle.net/10371/173074-
dc.description.abstractBackground: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. Aim: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov: NCT03221426-
dc.language영어-
dc.publisherFuture Medicine Ltd.-
dc.titleKEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.2217/fon-2018-0581-
dc.citation.journaltitleFuture Oncology-
dc.identifier.wosid000463965300003-
dc.identifier.scopusid2-s2.0-85063237152-
dc.citation.endpage952-
dc.citation.number9-
dc.citation.startpage943-
dc.citation.volume15-
dc.identifier.sci000463965300003-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordPlusSURGERY-
dc.subject.keywordPlusB7-H1-
dc.subject.keywordAuthoradjuvant therapy-
dc.subject.keywordAuthorchemotherapy-
dc.subject.keywordAuthorgastric cancer-
dc.subject.keywordAuthorgastroesophageal junction cancer-
dc.subject.keywordAuthorimmunotherapy-
dc.subject.keywordAuthorneoadjuvant therapy-
dc.subject.keywordAuthorpembrolizumab-
dc.subject.keywordAuthorsurgery-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share